Trial Profile
A Phase I Study of Immunotherapy With E6 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs E6 TCR (Primary) ; Aldesleukin
- Indications Cervical intraepithelial neoplasia
- Focus Adverse reactions
- 19 Oct 2020 Status changed from completed to discontinued.
- 31 Oct 2019 Status changed from discontinued to completed.
- 20 Sep 2019 Status changed from completed to discontinued.